GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (OTCPK:HBMHF) » Definitions » Land And Improvements

HBM Holdings (HBM Holdings) Land And Improvements : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is HBM Holdings Land And Improvements?

HBM Holdings's land and improvements for the quarter that ended in Dec. 2023 was $0.00 Mil.

HBM Holdings Land And Improvements Historical Data

The historical data trend for HBM Holdings's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HBM Holdings Land And Improvements Chart

HBM Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Land And Improvements
Get a 7-Day Free Trial - - - - -

HBM Holdings Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Land And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

HBM Holdings Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

HBM Holdings (HBM Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (OTCPK:HBMHF) » Definitions » Land And Improvements
Comparable Companies
HKSE:09939 HKSE:03681 HKSE:06996 HKSE:01875 HKSE:02197 HKSE:02126 HKSE:02185 HKSE:06998 HKSE:06628 HKSE:01228 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
02142:Hong Kong
Address
420 Fenglin Road, 12th Floor, Tower A, Fenglin International Plaza Phase II, Xuhui District, Shanghai, CHN, 200032
Website
https://www.harbourbiomed.com
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. Majority of revenue is generated from Europe.

HBM Holdings (HBM Holdings) Headlines

From GuruFocus

Harbour BioMed Announces Positive Profit Alert

By PRNewswire • 01-19-2024